<p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 獲取免費報告）股票在週五達到了新的 52 周高點。該公司交易最高價為 9.38 美元，最後交易價為 9.1220 美元，成交量為 440382 股。該股票此前收盤價為 8.81 美元。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>CRVS 已成為多份分析師報告的主題。巴克萊在 10 月 13 日（星期一）的一份研究報告中開始覆蓋 Corvus Pharmaceuticals。他們給予該公司的評級為 “增持”，目標價為 16.00 美元。瑞穗證券在 10 月 29 日（星期三）的一份研究報告中設定了 Corvus Pharmaceuticals 的目標價為 13.00 美元。韋斯評級在 10 月 8 日（星期三）的一份研究報告中重新發布了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，華爾街 Zen 在 11 月 8 日（星期六）的一份報告中將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。四位投資分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，Corvus Pharmaceuticals 的平均評級為 “適度買入”，共識目標價為 14.25 美元。</p>
<p><strong>查看我們關於 Corvus Pharmaceuticals 的最新研究報告</strong></p>
<h2>Corvus Pharmaceuticals 價格表現</h2>
<p>該公司的市值為 6.8056 億美元，市盈率為-17.09，貝塔值為 0.64。該公司的 50 日簡單移動平均線為 7.84 美元，200 日簡單移動平均線為 5.76 美元。</p>
<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近於 11 月 4 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.12 美元），超過分析師一致預期的（0.14 美元）2 美分。平均而言，研究分析師預計 Corvus Pharmaceuticals, Inc. 本年度每股收益將為-0.63 美元。</p>
<h2>機構投資者對 Corvus Pharmaceuticals 的看法</h2>
<p>幾家機構投資者最近買入和賣出了 CRVS 的股票。Quarry LP 在第三季度收購了價值約 27,000 美元的 Corvus Pharmaceuticals 新頭寸。Jain Global LLC 在第三季度購買了價值約 204,000 美元的 Corvus Pharmaceuticals 新股份。Brevan Howard Capital Management LP 在第三季度收購了價值約 113,000 美元的 Corvus Pharmaceuticals 新頭寸。美國銀行在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 14.5%。美國銀行目前擁有該公司 151,966 股股票，價值 1,120,000 美元，此前在上個季度又購買了 19,237 股。最後，Creative Planning 在第三季度購買了價值約 186,000 美元的 Corvus Pharmaceuticals 新股份。目前 46.64% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Corvus Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Corvus Pharmaceuticals</li>
<li>什麼是便士股票？全面指南</li>
<li>Kroger 股票分析：數字轉型、股息安全與 2026 年增長計劃</li>
<li>如何計算投資回報率（ROI）</li>
<li>加密礦工會轉向人工智能嗎？關於三家關鍵參與者的最新消息</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Corvus制藥

<p>Corvus 製藥（NASDAQ:CRVS）達到了新的 52 周高點，交易價格高達 9.38 美元。分析師的評級各不相同，巴克萊給予 “增持” 評級和 16 美元的目標價，而韋斯評級則發佈了 “賣出” 評級。該股票的共識評級為適度買入，目標價為 14.25 美元。機構投資者活躍，持股比例為 46.64%。Corvus 專注於針對各種疾病的免疫調節劑產品候選者</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $9.38 and last traded at $9.1220, with a volume of 440382 shares trading hands. The stock had previously closed at $8.81.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（納斯達克代碼：CRVS - 獲取免費報告）股票在週五達到了新的 52 周高點。該公司交易最高價為 9.38 美元，最後交易價為 9.1220 美元，成交量為 440382 股。該股票此前收盤價為 8.81 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>CRVS has been the subject of a number of analyst reports. Barclays initiated coverage on Corvus Pharmaceuticals in a research note on Monday, October 13th. They issued an &#34;overweight&#34; rating and a $16.00 price target for the company. Mizuho set a $13.00 price objective on Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $14.25.</p>
<div class="lb-trans"><p>CRVS 已成為多份分析師報告的主題。巴克萊在 10 月 13 日（星期一）的一份研究報告中開始覆蓋 Corvus Pharmaceuticals。他們給予該公司的評級為 “增持”，目標價為 16.00 美元。瑞穗證券在 10 月 29 日（星期三）的一份研究報告中設定了 Corvus Pharmaceuticals 的目標價為 13.00 美元。韋斯評級在 10 月 8 日（星期三）的一份研究報告中重新發布了對 Corvus Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，華爾街 Zen 在 11 月 8 日（星期六）的一份報告中將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。四位投資分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat 的數據，Corvus Pharmaceuticals 的平均評級為 “適度買入”，共識目標價為 14.25 美元。</p>
</div><p><strong>View Our Latest Research Report on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Corvus Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 價格表現</h2>
</div><p>The firm has a market capitalization of $680.56 million, a PE ratio of -17.09 and a beta of 0.64. The business has a 50-day simple moving average of $7.84 and a 200-day simple moving average of $5.76.</p>
<div class="lb-trans"><p>該公司的市值為 6.8056 億美元，市盈率為-17.09，貝塔值為 0.64。該公司的 50 日簡單移動平均線為 7.84 美元，200 日簡單移動平均線為 5.76 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（納斯達克代碼：CRVS - 獲取免費報告）最近於 11 月 4 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.12 美元），超過分析師一致預期的（0.14 美元）2 美分。平均而言，研究分析師預計 Corvus Pharmaceuticals, Inc. 本年度每股收益將為-0.63 美元。</p>
</div><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Corvus Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of CRVS. Quarry LP acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000. Jain Global LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $204,000. Brevan Howard Capital Management LP acquired a new position in shares of Corvus Pharmaceuticals during the third quarter valued at about $113,000. Bank of America Corp DE boosted its stake in Corvus Pharmaceuticals by 14.5% in the 3rd quarter. Bank of America Corp DE now owns 151,966 shares of the company's stock worth $1,120,000 after purchasing an additional 19,237 shares in the last quarter. Finally, Creative Planning purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter worth approximately $186,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者最近買入和賣出了 CRVS 的股票。Quarry LP 在第三季度收購了價值約 27,000 美元的 Corvus Pharmaceuticals 新頭寸。Jain Global LLC 在第三季度購買了價值約 204,000 美元的 Corvus Pharmaceuticals 新股份。Brevan Howard Capital Management LP 在第三季度收購了價值約 113,000 美元的 Corvus Pharmaceuticals 新頭寸。美國銀行在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 14.5%。美國銀行目前擁有該公司 151,966 股股票，價值 1,120,000 美元，此前在上個季度又購買了 19,237 股。最後，Creative Planning 在第三季度購買了價值約 186,000 美元的 Corvus Pharmaceuticals 新股份。目前 46.64% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司，專注於開發和商業化免疫調節劑產品候選藥物，以治療實體癌症、T 細胞淋巴瘤、自身免疫性疾病、過敏性疾病和傳染病。其主要產品候選藥物是 soquelitinib（CPI-818），這是一種選擇性共價抑制劑，針對白細胞介素 2 誘導的 T 細胞激酶（ITK），目前正在進行多中心的 1/1b 期臨牀試驗，治療外周 T 細胞淋巴瘤、實體腫瘤和特應性皮炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>Kroger Stock Analysis: Digital Pivot, Dividend Safety &amp; 2026 Growth Plan</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Corvus Pharmaceuticals</li>
<li>什麼是便士股票？全面指南</li>
<li>Kroger 股票分析：數字轉型、股息安全與 2026 年增長計劃</li>
<li>如何計算投資回報率（ROI）</li>
<li>加密礦工會轉向人工智能嗎？關於三家關鍵參與者的最新消息</li>
<li>投資者必須瞭解的場外交易（OTC）股票</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Corvus 製藥（NASDAQ:CRVS）創下新的 12 個月高點 - 以下是發生的事情